Key result
Selective arginase II inhibitors L207-0525 and L327-0346 combined with tadalafil significantly prevented the development of monocrotaline-induced pulmonary hypertension in rats.
Why the study?
Given the fundamental regulatory role of endothelium in pulmonary hypertension pathogenesis, the study evaluated the protective effects of selective arginase II inhibitors combined with tadalafil in monocrotaline-induced pulmonary hypertension.
Does the combination of selective arginase II inhibitors and tadalafil prevent the development of pulmonary hypertension in a monocrotaline rat model?
Does the combination of selective arginase II inhibitors and tadalafil prevent the development of pulmonary hypertension in a monocrotaline rat model?
The combination of selective arginase II inhibitors and low-dose tadalafil demonstrates additive protective effects against the development of monocrotaline-induced pulmonary hypertension in rats.
Hypothesis-generating in rat pulmonary hypertension; leaves open translation of arginase II inhibition plus tadalafil to human disease.
No takes yet. Share an insight, caveat, or question.
Koklin et al. (2019) studied Monocrotaline-induced pulmonary hypertension (n=10). Arginase II inhibitors L207-0525 and L327-0346 combined with tadalafil was evaluated on Coefficient of endothelial dysfunction, systolic pressure in the right ventricle, Fulton, RV/BW and WT indices. Selective arginase II inhibitors L207-0525 and L327-0346 combined with tadalafil significantly prevented the development of monocrotaline-induced pulmonary hypertension in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: